Erin Lavelle’s Post

𝐀𝐛𝐛𝐕𝐢𝐞 𝐩𝐚𝐲𝐬 $𝟏𝟎𝐁 𝐭𝐨 𝐚𝐜𝐪𝐮𝐢𝐫𝐞 𝐈𝐦𝐦𝐮𝐧𝐨𝐆𝐞𝐧, 𝐛𝐲 𝐝𝐨𝐮𝐛𝐥𝐢𝐧𝐠 𝐝𝐨𝐰𝐧 𝐨𝐧 𝐫𝐞𝐝-𝐡𝐨𝐭 𝐀𝐃𝐂 (𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲-𝐝𝐫𝐮𝐠 𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞) 𝐜𝐚𝐧𝐜𝐞𝐫 𝐟𝐢𝐞𝐥𝐝 In November 2023, AbbVie is shelling out $10.1 #billion in #cash to acquire maker of #ovariancancertreatment Elahere by ImmunoGen, Inc., which has won approval form FDA (Food and Drug Administration). This acquisition has allowed AbbVie’s entry into solid #tumorspace and thus, strengthen its position in #oncology pipeline. ➤𝐎𝐭𝐡𝐞𝐫 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐫𝐞𝐩𝐨𝐫𝐭:https://bit.ly/3RnYlVW #antibodydrugconjugates #abbvie #Immunogen #prophecy #marketresearch #prophecymarketinsights

Join us on Feb. 8 when @Bill Byrom and @Anthony Todd Everhart will talk about recent updates to FDA guidances, practical applications of computerized adaptive tests (CATs), and leveraging PROs in early-phase oncology trials. Engage with industry experts, explore use cases, and gain practical tips for implementing PROMs throughout #oncology drug development (from early phase to phase III). Secure your spot today: https://lnkd.in/eMP5Xj-z #oncologytrials #eCOA #webinar #lifesciencesevents

Great to see Scancell being covered by the DailyMail.com as a company working on a potential future blockbuster treatment. Our Chief Executive Officer, Lindy Durrant, was interviewed by joanne hart to discuss the science behind Scancell’s innovative approach, and how it has the potential to revolutionise the oncology field with its cancer vaccines.   Read the full article here: https://lnkd.in/dGNGdY79   #CancerVaccines #Oncology #ImmunoOncology #Biotechnology

Dr. Gerrina Ruiter, pulmonologist and part of our Early Drug Development Team leading several Phase 1 trials, explained at ESMO the limitations of previous HER2 agents tested in solid tumors and highlighted the encouraging preliminary results of the BEAMION Lung-1 trial of zongertinib in HER2–mutant solid tumors. Watch the full video here: https://lnkd.in/eH3P8mVZ Early Drug Development Center - NKI #HER2 #lungcancer #phase1 #drugdevelopment

Presenting the August 2023 issue of Technology Newsletter from Sidvim! A summary of important happenings in the technology space in Pharma.   The key topics covered in this month’s edition are:   1. Drug-Dendrimer conjugates as an enabling drug delivery vehicle for oncology therapeutics 2. Drug-Peptide conjugates as novel sustained intraocular drug delivery systems  

> CordenPharma's Highly Potent & Oncology Platform Director Brittany L. Hayes, Ph.D. is interviewed by Life Sciences Knowledge Hub at CPHI Barcelona. Topics include an overview of our Highly Potent & Oncology platform providing early to late phase highly potent APIs & Drug Products with complex molecules, small molecules, hipo peptides, or linkers for ADCs in tablets, capsules and injectables containing some of the most potent substances on the planet. CordenPharma's recent innovations in the highly potent market include our new bioavailability enhancement capabilities with Hot Melt Extrusion, Spray Drying, Jet & Nano-milling and solutions for permeability challenges, as well as a GMP area with Hot Melt Extrusion and encapsulation expansions. https://lnkd.in/e5Q8uFFk #CordenPharma #highlypotent #oncology #bioavailability #hotmelt #spraydrying #tablets #capsules #injectables #lipids #oralsoliddose #osd #apis #drugdevelopment #drugproduct

Engage with industry experts, explore use cases, and gain practical tips for implementing PROMs throughout #oncology drug development (from early phase to phase III) in our webinar Feb. 8. Secure your spot today: https://lnkd.in/eKA6Kr4Z #oncologytrials #eCOA #webinar #lifesciencesevents

Engage with industry experts, explore use cases, and gain practical tips for implementing PROMs throughout #oncology drug development (from early phase to phase III) in our webinar Feb. 8. Secure your spot today: https://lnkd.in/ek7BT3jd #oncologytrials #eCOA #webinar #lifesciencesevents